Tablets
Professed Standard Therapeutic Classification: Other Protein Kinase Inhibitors (L01EX21)
TEPMETKO has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for TEPMETKO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site
TEPMETKO is indicated for: